Home
HelpTest Code PNRCH Drug Immunoassay Panel, Urine
Reporting Name
Drug Immunoassay Panel, UUseful For
Detecting drug use involving barbiturates, cocaine, and carboxy-tetrahydrocannabinol
This test is not intended for use in employment-related testing.
Reflex Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| BARBU | Barbiturates Confirmation, U | Yes | No |
| COKEU | Cocaine and metabolite Conf, U | Yes | No |
| THCU | Carboxy-THC Confirmation, U | Yes | No |
Testing Algorithm
Testing begins with screening tests for drugs of abuse including barbiturates, cocaine, and tetrahydrocannabinol.
Positive results are confirmed and quantitated by definitive methods, gas chromatography mass spectrometry for barbiturates, cocaine, and metabolites and liquid chromatography tandem mass spectrometry for tetrahydrocannabinol metabolites at an additional charge.
Method Name
Only orderable as part of profile. For more information see:
-CSMPU / Controlled Substance Monitoring Panel, Random, Urine.
-ADMPU / Addiction Medicine Profile with Reflex, 22 Drug Classes, High Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine
-CSMEU / Controlled Substance Monitoring Enhanced Profile with Reflex, 21 Drug Classes, High Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine
Immunoassay
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Specimen Type
UrineOrdering Guidance
The test does not screen for drug classes other than those listed in Testing Algorithm.
Specimen Required
Only orderable as part of profile. For more information see:
-CSMPU / Controlled Substance Monitoring Panel, Random, Urine
-ADMPU / Addiction Medicine Profile with Reflex, 22 Drug Classes, High Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine
-CSMEU / Controlled Substance Monitoring Enhanced Profile with Reflex, 21 Drug Classes, High Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine
Specimen Minimum Volume
20 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Urine | Refrigerated (preferred) | 14 days | |
| Frozen | 14 days | ||
| Ambient | 72 hours |
Reject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitabilityReference Values
Only orderable as part of profile. For more information see:
-CSMPU / Controlled Substance Monitoring Panel, Random, Urine
-ADMPU / Addiction Medicine Profile with Reflex, 22 Drug Classes, High Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine
-CSMEU / Controlled Substance Monitoring Enhanced Profile with Reflex, 21 Drug Classes, High Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine
Negative
Screening cutoff concentrations:
Barbiturates: 200 ng/mL
Cocaine (benzoylecgonine-cocaine metabolite): 150 ng/mL
Tetrahydrocannabinol carboxylic acid: 50 ng/mL
This report is intended for use in clinical monitoring or management of patients. It is not intended for use in employment-related testing.
Day(s) Performed
Monday through Saturday
CPT Code Information
80307
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| PNRCH | Drug Immunoassay Panel, U | 87428-9 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 2574 | Barbiturates | 70155-7 |
| 21652 | Cocaine | 19359-9 |
| 2664 | Tetrahydrocannabinol | 19415-9 |
Secondary ID
65061Specimen Retention Time
14 daysTest Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.Clinical Information
This test uses the simple screening technique that involves immunoassay testing for drugs by class. All positive immunoassay screening results are confirmed by either gas chromatography mass spectrometry (GC-MS) or liquid chromatography tandem mass spectrometry (LC-MS/MS) and quantitated before a positive result is reported.
This assay was designed to test for and confirm by GC-MS the following:
-Barbiturates
-Cocaine
This assay was designed to test for and confirm by LC-MS/MS the following:
-Carboxy-tetrahydrocannabinol
This test is intended to be used in a setting where the test results can be used to make a definitive diagnosis.
Interpretation
A positive result derived by this testing indicates that the patient has used one of the drugs detected by these techniques in the recent past.
For information about drug testing, including estimated detection times and Result Interpretations, see Controlled Substance Monitoring on MayoClinicLabs.com.
Cautions
No significant cautionary statements
Clinical Reference
1. Baselt RC: Disposition of Toxic Drugs and Chemical in Man. 12th ed. Biomedical Publications; 2020:2343
2. Brunton LL, Hilal-Dandan R, Knollmann BC, eds. In: Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 13th ed. McGraw-Hill; 2018
3. Langman LJ, Bechtel LK, Holstege CP. Clinical toxicology. In: Rifai N, Chiu RWK, Young I, Burnham CAD, Wittwer CT, eds. Tietz Textbook of Laboratory Medicine. 7th ed. Elsevier; 2023:chap 43
4. Jannetto PJ, Bratanow NC, Clark WA, et al. Executive summary: American Association of Clinical Chemistry Laboratory Medicine Practice Guideline-Using clinical laboratory tests to monitor drug therapy in pain management patients. J Appl Lab Med. 2018;2(4):489-526
Method Description
The barbiturate, cocaine metabolite, and tetrahydrocannabinol metabolite assays are based on the kinetic interaction of microparticles in a solution as measured by changes in light transmission. In the absence of sample drug, soluble drug conjugates bind to antibody-bound microparticles, causing the formation of particle aggregates. As the aggregation reaction proceeds in the absence of sample drug, the absorbance increases. When a urine sample contains the drug in question, this drug competes with the drug derivative conjugate for microparticle-bound antibody. Antibody bound to sample drug is no longer available to promote particle aggregation, and subsequent particle lattice formation is inhibited. The presence of sample drug diminishes the increasing absorbance in proportion to the concentration of drug in the sample. Sample drug content is determined relative to the value obtained for a known cutoff concentration of drug.(Package inserts: BARB. Roche Diagnostics; V 13.0, 09/2021; THC2. Roche Diagnostics; V 13.0, 03/2022; COC2. Roche Diagnostics; V 9.0, 03/2019)